IRIS
DI RAIMONDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 32.552
EU - Europa 16.346
AS - Asia 15.804
SA - Sud America 2.830
AF - Africa 1.467
Continente sconosciuto - Info sul continente non disponibili 1.091
OC - Oceania 39
Totale 70.129
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 31.143
SG - Singapore 8.586
RU - Federazione Russa 4.806
CN - Cina 3.894
IT - Italia 3.234
IE - Irlanda 2.660
UA - Ucraina 2.424
BR - Brasile 2.275
VN - Vietnam 1.190
CA - Canada 1.090
FR - Francia 895
CI - Costa d'Avorio 686
SE - Svezia 502
KR - Corea 457
GB - Regno Unito 420
IN - India 383
DE - Germania 365
NG - Nigeria 334
BD - Bangladesh 273
AR - Argentina 191
MX - Messico 160
NL - Olanda 151
PL - Polonia 146
SN - Senegal 143
FI - Finlandia 140
JP - Giappone 122
HK - Hong Kong 117
IQ - Iraq 116
ZA - Sudafrica 109
UZ - Uzbekistan 98
ES - Italia 96
CH - Svizzera 94
EC - Ecuador 90
TR - Turchia 90
AT - Austria 72
CO - Colombia 72
VE - Venezuela 64
CZ - Repubblica Ceca 59
ID - Indonesia 59
BE - Belgio 57
PK - Pakistan 54
GR - Grecia 53
CL - Cile 49
MA - Marocco 49
LB - Libano 43
LT - Lituania 38
SA - Arabia Saudita 36
JO - Giordania 33
KE - Kenya 33
AU - Australia 30
PY - Paraguay 30
IR - Iran 28
JM - Giamaica 28
AE - Emirati Arabi Uniti 27
PH - Filippine 25
TN - Tunisia 25
EG - Egitto 24
IL - Israele 24
CR - Costa Rica 22
PE - Perù 22
DZ - Algeria 21
BO - Bolivia 19
MY - Malesia 19
AZ - Azerbaigian 18
BJ - Benin 18
EU - Europa 18
KZ - Kazakistan 18
RO - Romania 18
BG - Bulgaria 16
RS - Serbia 16
DO - Repubblica Dominicana 15
HN - Honduras 14
OM - Oman 14
TT - Trinidad e Tobago 13
UY - Uruguay 13
AL - Albania 11
NO - Norvegia 11
PS - Palestinian Territory 11
SI - Slovenia 11
TH - Thailandia 11
NI - Nicaragua 10
SV - El Salvador 10
HR - Croazia 9
KW - Kuwait 9
PA - Panama 9
GT - Guatemala 8
PR - Porto Rico 8
ET - Etiopia 7
HU - Ungheria 7
KG - Kirghizistan 7
NP - Nepal 7
NZ - Nuova Zelanda 7
PT - Portogallo 7
BB - Barbados 5
BH - Bahrain 5
MT - Malta 5
AO - Angola 4
DK - Danimarca 4
GD - Grenada 4
KH - Cambogia 4
Totale 68.977
Salva come PNG Salva come JPEG
Città #
Dallas 5.160
Singapore 4.840
Santa Clara 2.994
Jacksonville 2.644
Dublin 2.639
San Jose 2.431
Chandler 2.135
Moscow 1.970
Ashburn 1.589
Boardman 1.117
Chicago 986
Catania 964
Council Bluffs 777
Nanjing 751
Cambridge 720
Andover 716
Lawrence 716
Lauterbourg 707
Abidjan 684
Toronto 674
Los Angeles 567
Houston 541
Hefei 501
Beijing 466
Seoul 456
Des Moines 424
Ho Chi Minh City 396
San Mateo 387
New York 300
Hanoi 271
Nanchang 263
Wilmington 263
Civitanova Marche 229
São Paulo 220
Buffalo 212
Saint Petersburg 182
Shenyang 180
Hebei 176
Abuja 172
Ottawa 155
Jiaxing 148
Dakar 142
Florence 141
Rome 138
Changsha 135
Montreal 129
Lagos 126
Orem 126
Milan 125
Tianjin 110
Palermo 109
Tokyo 109
Warsaw 107
Hong Kong 106
Grafing 96
Kochi 92
Brooklyn 88
Dong Ket 87
Stockholm 87
Seattle 86
Denver 80
London 79
Phoenix 74
Johannesburg 72
Munich 71
Boston 70
Rio de Janeiro 69
Washington 69
Atlanta 65
Poplar 63
Chennai 62
San Francisco 60
Helsinki 53
Belo Horizonte 51
The Dalles 51
Amsterdam 50
Columbus 49
Hangzhou 49
Brussels 48
Mexico City 48
Mumbai 47
Tashkent 46
Lappeenranta 44
Redondo Beach 44
Naples 42
Turku 42
Haiphong 40
Den Haag 39
Bari 38
Norwalk 38
Ankara 36
Port Harcourt 36
Baghdad 35
Da Nang 35
Kunming 35
Messina 35
Paris 34
Frankfurt am Main 33
Manchester 33
Pune 33
Totale 45.860
Salva come PNG Salva come JPEG
Nome #
Il Rasario. Semeiotica medica 357
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 301
Childhood neurofibromatosis type 2 (NF2) and related disorders: From bench to bedside and biologically targeted therapies [Neurofibromatosi tipo 2 (NF2) e sindromi correlate in età infantile: dalla biologia molecolare alla pratica clinica e nuove terapie con farmaci biologici] 286
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload 236
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 229
BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia 223
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 222
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis 220
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 209
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 204
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM) 203
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 203
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen 184
Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib 184
Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. 183
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 183
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 183
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 180
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 176
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 174
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 174
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 169
A PHASE III STUDY OF ENOXAPARIN VERSUS ASPIRIN VERSUS LOW-DOSE WARFARIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED UP-FRONT WITH THALIDOMIDE BASED-REGIMENS 169
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 168
Hedgehog signaling pathways in multiple myeloma 168
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 168
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 167
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 167
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 167
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 165
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 165
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 163
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 163
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 163
A PHASE 3, RANDOMIZED CLINICAL STUDY OF AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE AT DIAGNOSIS 162
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 162
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 162
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 161
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. 161
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol 161
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 161
A case of high-risk AML in a patient with advanced systemic mastocytosis 160
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 158
Comprehensive Analysis of TSPAN32 Regulatory Networks and Their Role in Immune Cell Biology 157
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 156
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 156
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia 155
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells 154
A snapshot of asparaginase-induced liver insufficiency. 153
Acute pre-hepatic portal thrombosis: diagnosis and therapy 152
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD 152
A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents 152
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 151
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 151
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 150
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment 149
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 149
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 149
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 148
A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis 148
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 148
Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience 147
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 147
Analysis of metabolic parameters coming from basal and interim PET in hodgkin lymphoma 147
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over 146
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 146
ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN'S LYMPHOMA 145
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 145
A GLOBAL PROGRESSION RISK SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: THE NEVER-ENDING STORY 145
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 145
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 144
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 143
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia 143
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 143
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 143
Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells 142
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 142
Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification 141
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 140
A NEW CYTOGENETIC ABNORMALITY, T(1;4) (P22;P16) IN AML M4 PATIENT AFTER CHEMOTHERAPY TREATMENT 140
Mesenchymal stem cells (MSC) promotes tumor microenvironment transformation driving Granulocyte-like Myeloid Derived Suppressor Cells (G-MDSC) activation in Smoldering and Multiple Myeloma patients 140
A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients 139
Multiple Myeloma in 2023 Ways: From Trials to Real Life 138
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma 138
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network 137
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases 137
Acute myeloid leukemia in elderly patients. 136
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 135
Bone turnover markers in patients with type 1 Gaucher disease 135
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 134
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 134
A New Method To Evaluate the Prognostic Value of Response to Prednisone Pre-Treatment in Adult (15–60 Yrs) Patients with Acute Lymphoblastic Leukemia: Results of the GIMEMA LAL 2000 Study 133
Eventi avversi e trigger C12: Stroke in ospedale 133
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 132
CIRCULATING ARGINASE-1 IN SERUM IS A NOVEL BIO-MARKERIN HODGKIN LYMPHOMA 132
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 132
A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones? 132
Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study 131
CD200 EXPRESSION ON MYELOMA CELLS AND ANTITUMOR IMMUNITY 131
Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia 131
Totale 16.278
Salva come PNG Salva come JPEG
Categoria #
all - tutte 251.364
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 251.364
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.534 0 763 22 43 872 42 762 175 524 28 122 1.181
2022/20237.429 743 273 104 503 714 1.384 24 1.266 1.976 58 274 110
2023/20243.154 209 432 133 251 142 514 68 206 15 86 676 422
2024/202512.800 99 2.090 837 448 2.795 1.044 380 521 1.091 1.399 960 1.136
2025/202629.450 1.673 1.754 5.013 1.882 4.775 5.439 3.920 613 1.547 1.520 784 530
2026/20271.763 651 1.112 0 0 0 0 0 0 0 0 0 0
Totale 70.129